{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:59:18Z","timestamp":1790531958639,"version":"4.1.0"},"reference-count":51,"publisher":"Impact Journals, LLC","issue":"37","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,5,15]]},"DOI":"10.18632\/oncotarget.25191","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T15:10:34Z","timestamp":1526397034000},"page":"24576-24589","source":"Crossref","is-referenced-by-count":43,"title":["Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples"],"prefix":"10.18632","volume":"9","author":[{"given":"David K.","family":"Edwards V","sequence":"first","affiliation":[{"name":"Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Tyler","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hibery","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rofelty","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina Qiuying","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Lee","sequence":"additional","affiliation":[{"name":"Array BioPharma, Boulder, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chantry","sequence":"additional","affiliation":[{"name":"Array BioPharma, Boulder, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon K.","family":"McWeeney","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"},{"name":"Howard Hughes Medical Institute, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Spurgeon","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc M.","family":"Loriaux","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Jemal","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Lichter","year":"2000","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PPO.0b013e31826c5810","article-title":"Inhibitors of B-cell receptor signaling for patients with B-cell malignancies","volume":"18","author":"Kipps","year":"2012","journal-title":"Cancer J"},{"key":"4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","article-title":"Clinical significance of macrophage heterogeneity in human malignant tumors","volume":"105","author":"Takeya","year":"2014","journal-title":"Cancer Sci"},{"key":"5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.it.2011.12.001","article-title":"Differential macrophage programming in the tumor microenvironment","volume":"33","author":"Coussens","year":"2012","journal-title":"Trends Immunol"},{"key":"6","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1038\/bcj.2015.108","article-title":"Nurse-like cells impact on disease progression in chronic lymphocytic leukemia","volume":"6","author":"Ysebaert","year":"2016","journal-title":"Blood Cancer J"},{"key":"7","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3109\/10428194.2011.568078","article-title":"Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia","volume":"52","author":"Fourni\u00e9","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"8","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Kipps","year":"2000","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3109\/10428194.2014.991731","article-title":"Nurse like cells: chronic lymphocytic leukemia associated macrophages","volume":"56","author":"Ysebaert","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/leu.2010.306","article-title":"Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14+ cells from peripheral blood","volume":"25","author":"Mertens","year":"2011","journal-title":"Leukemia"},{"key":"11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bcmd.2012.12.003","article-title":"Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages?","volume":"50","author":"Dmoszy\u0144ska","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.24376","article-title":"Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Hematol"},{"key":"13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/0008-5472.CAN-15-0869","article-title":"M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment","volume":"76","author":"De Baetselier","year":"2016","journal-title":"Cancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/320277a0","article-title":"Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus","volume":"320","author":"Ullrich","year":"1986","journal-title":"Nature"},{"key":"15","first-page":"9","article-title":"Nucleotide sequence and structural organization of the human FMS proto-oncogene","volume":"4","author":"Galibert","year":"1989","journal-title":"Oncogene Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.1154370","article-title":"Discovery of a cytokine and its receptor by functional screening of the extracellular proteome","volume":"320","author":"Qin","year":"2008","journal-title":"Science"},{"key":"17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1083\/jcb.85.1.153","article-title":"Specific interaction of murine colony-stimulating factor with mononuclear phagocytic cells","volume":"85","author":"Stanley","year":"1980","journal-title":"J Cell Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1083\/jcb.91.3.848","article-title":"Distribution of cells bearing receptors for a colony-stimulating factor (CSF-1) in murine tissues","volume":"91","author":"Stanley","year":"1981","journal-title":"J Cell Biol"},{"key":"19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/274168a0","article-title":"Induction of macrophage production and proliferation by a purified colony stimulating factor","volume":"274","author":"Lin","year":"1978","journal-title":"Nature"},{"key":"20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1171461","article-title":"Hematopoietic cytokines can instruct lineage choice","volume":"325","author":"Schroeder","year":"2009","journal-title":"Science"},{"key":"21","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2009-08-237412","article-title":"Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy","volume":"115","author":"Wu","year":"2010","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.celrep.2016.01.042","article-title":"Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression","volume":"14","author":"Corti","year":"2016","journal-title":"Cell Reports"},{"key":"23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/leu.2015.305","article-title":"Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo","volume":"30","author":"Seiffert","year":"2016","journal-title":"Leukemia"},{"key":"24","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-15-3099","article-title":"Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia","volume":"22","author":"Wilcox","year":"2016","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1073\/pnas.0502000102","article-title":"Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580","volume":"102","author":"Lin","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"26","first-page":"A252","article-title":"Abstract A252: A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers. Mol Cancer Ther","volume":"12","author":"Rush","year":"2014","journal-title":"American Association for Cancer Research"},{"key":"27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Mertens","year":"2015","journal-title":"Nature"},{"key":"28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Belver","year":"2015","journal-title":"Nature"},{"key":"29","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1080\/10428190412331272703","article-title":"Microenvironmental interactions and survival of CLL B-cells","volume":"45","author":"Reed","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"30","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Gribben","year":"2012","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"32","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Ervin","year":"2014","journal-title":"N Engl J Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Bilotti","year":"2015","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Yilmaz","year":"2014","journal-title":"N Engl J Med"},{"key":"36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia","volume":"1","author":"Flynn","year":"2015","journal-title":"JAMA Oncol"},{"key":"37","first-page":"59","article-title":"Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor","volume":"865","author":"Bottazzi","year":"1986","journal-title":"Biochim Biophys Acta"},{"key":"38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Mantovani","year":"2001","journal-title":"Lancet"},{"key":"39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Coussens","year":"2014","journal-title":"Cancer Cell"},{"key":"40","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","article-title":"Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia","volume":"99","author":"Kipps","year":"2002","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/leu.2016.261","article-title":"B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia","volume":"30","author":"Bertilaccio","year":"2016","journal-title":"Leukemia"},{"key":"42","doi-asserted-by":"crossref","first-page":"e0125203","DOI":"10.1371\/journal.pone.0125203","article-title":"CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma","volume":"10","author":"Garc\u00eda","year":"2015","journal-title":"PLoS One"},{"key":"43","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Muller-Hermelink","year":"2010","journal-title":"N Engl J Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1309\/AJCPR92TDDFARISU","article-title":"CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma","volume":"141","author":"Huh","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2326-6066.CIR-14-0232","article-title":"TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy","volume":"3","author":"Coussens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0000000000000132","article-title":"Myeloid Cells as Targets for Therapy in Solid Tumors","volume":"21","author":"Coussens","year":"2015","journal-title":"Cancer J"},{"key":"47","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1038\/bcj.2015.74","article-title":"Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients","volume":"5","author":"Poupot","year":"2015","journal-title":"Blood Cancer J"},{"key":"48","doi-asserted-by":"publisher","first-page":"65968","DOI":"10.18632\/oncotarget.11782","article-title":"Ibrutinib modifies the function of monocyte\/macrophage population in chronic lymphocytic leukemia","volume":"7","author":"Marasca","year":"2016","journal-title":"Oncotarget"},{"key":"49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening","volume":"73","author":"Oh","year":"2013","journal-title":"Cancer Res"},{"key":"50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"51","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng0506-500","article-title":"GenePattern 2.0","volume":"38","author":"Mesirov","year":"2006","journal-title":"Nat Genet"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T18:15:45Z","timestamp":1589048145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":51,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2018,5,15]]}},"alternative-id":["25191","29872489"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25191","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]}}}